open access

Vol 7, No 1 (2016)
Case report
Published online: 2016-08-03
Get Citation

The efficacy of lenalidomide in the patient with plasma cell myeloma coexisting with myelodysplatic syndrome associated with isolated del 5q–

Agata Malenda, Agnieszka Kołkowska-Leśniak, Anna Szumera-Ciećkiewicz, Ewa Lech-Marańda, Krzysztof Warzocha
DOI: 10.5603/Hem.2016.0006
·
Hematologia 2016;7(1):77-84.

open access

Vol 7, No 1 (2016)
CASE REPORTS
Published online: 2016-08-03

Abstract

Treatment-related extension of survival has recently been observed in patients with plasma cell myeloma (PCM). However, chemotherapy also increases he incidence of other cancers for this patient group; myelodysplastic syndrome (MDS) being a classic example. A rare case-study is presented of a patient diagnosed with PCM coexisting with MDS associated with isolated del 5q– (MDS 5q–). After lenalidomide treatment, partial remission from PCM was observed, also accompanied by, partial cytogenic remission of MDS 5q–.

Abstract

Treatment-related extension of survival has recently been observed in patients with plasma cell myeloma (PCM). However, chemotherapy also increases he incidence of other cancers for this patient group; myelodysplastic syndrome (MDS) being a classic example. A rare case-study is presented of a patient diagnosed with PCM coexisting with MDS associated with isolated del 5q– (MDS 5q–). After lenalidomide treatment, partial remission from PCM was observed, also accompanied by, partial cytogenic remission of MDS 5q–.

Get Citation

Keywords

plasma cell myeloma, myelodysplatic syndrome, deletion 5q–, lenalidomide

About this article
Title

The efficacy of lenalidomide in the patient with plasma cell myeloma coexisting with myelodysplatic syndrome associated with isolated del 5q–

Journal

Hematology in Clinical Practice

Issue

Vol 7, No 1 (2016)

Article type

Case report

Pages

77-84

Published online

2016-08-03

DOI

10.5603/Hem.2016.0006

Bibliographic record

Hematologia 2016;7(1):77-84.

Keywords

plasma cell myeloma
myelodysplatic syndrome
deletion 5q–
lenalidomide

Authors

Agata Malenda
Agnieszka Kołkowska-Leśniak
Anna Szumera-Ciećkiewicz
Ewa Lech-Marańda
Krzysztof Warzocha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.